New study aims to perfect antibiotic dosing for tiny infants
NCT ID NCT04916951
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how two common oral antibiotics, amoxicillin and cephalexin, work in newborns and young infants. Researchers enrolled 72 babies already receiving these or other antibiotics in the hospital. By taking small blood samples over time, they measured drug levels to determine the best doses for treating infections common in infants. The goal is to ensure the antibiotics are effective while avoiding underdosing or side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
72 people
The number who actually took part.
- Started
-
Jul 2021
- Finished
-
Nov 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
1 day to 60 days
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients admitted to Children's Hospital Colorado derived from two groups: * Group 1-patients specifically receiving enteral amoxicillin (with or without clavulanate) or cephalexin for any clinical indication; * Group 2-patients receiving any IV antibiotic who are tolerating full enteral feeds and/or enteral medications. Exclusion Criteria: * Across both groups, exclusion criteria are: (1) weight \<2kg, (2) renal dysfunction, including the use of any renal replacement therapy, (3) significant β-lactam allergy, (4) GI disorders significantly impairing drug absorption, (5) use of external circuits that would affect the study drug's volume of distribution (e.g. ECMO), and (6) clinically significant anemia precluding study-related blood draws.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Neonatal infection are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Epidurals and infections: a 49,000-Birth investigation
- Newborn blood spots may reveal hidden risks from common virus
- Massive study tracks meningitis trends in 10,000 kids
- Quick swab test could prevent newborn sepsis
- Booster shot for Moms-to-Be could shield newborns from deadly infections
- Could a Parent's nose bacteria shield newborns from staph?